SOUTH SAN FRANCISCO, Calif. — Mission Bio, a leader in single-cell multi-omics for precision medicine, announced the appointment of Zivjena Vucetic, M.D., Ph.D., as Chief Medical Officer. A physician-scientist with more than 15 years of experience in diagnostics, biomarker development, and regulatory strategy, Dr. Vucetic will lead Mission Bio’s clinical adoption initiatives and biopharma collaborations, strengthening the company’s role in guiding therapeutic development through its Tapestri platform.
Dr. Vucetic most recently served as Chief Medical Officer and Senior Vice President at Beckman Coulter Diagnostics, where she led medical strategy across a multibillion-dollar portfolio and advanced blood-based biomarker programs for Alzheimer’s and other neurodegenerative diseases. Prior to that, she served as Chief Medical Officer at Karius, where she helped achieve FDA Breakthrough Device designation for an infectious disease sequencing test. Her earlier leadership roles at Clinical Genomics, Ortho Clinical Diagnostics, and Fujirebio Diagnostics included driving validation programs, payer engagement, and partnerships with pharmaceutical and academic institutions.
“Zivjena brings a proven record of translating breakthrough science into clinical adoption at global scale,” said Brian Kim, Chief Executive Officer of Mission Bio. “Her leadership strengthens our ability to deliver evidence and confidence to our partners as they bring precision therapies to patients. With her expertise, Mission Bio is positioned to set the standard for how single-cell multi-omics informs the next generation of drug development and clinical research.”
“Throughout my career, I have focused on building the clinical evidence and regulatory confidence required to move new diagnostics from concept to adoption,” said Dr. Vucetic. “Mission Bio’s single-cell multi-omics platform carries the same potential to shift standards in precision medicine, and I am eager to help extend its impact across cancer, cell and gene therapy, and therapeutic development.”
Mission Bio’s Tapestri Platform is used worldwide by biopharma companies and academic institutions to detect rare cell populations, profile clonal heterogeneity, validate biomarkers, and support cell and gene therapy programs. With ongoing advancements in tri-omics, sample multiplexing, and its expanding Pharma Assay Development service line, Mission Bio continues to extend its platform from discovery research into translational and late-stage therapeutic development.
